Vicore Pharma Holding publish annual report for 2016
We achieved the milestones we determined for 2016. Now, we will continue to develop C21 into a future drug for the treatment of idiopathic pulmonary fibrosis says Per Jansson, CEO of Vicore Pharma Holding AB.Important events during the financial year · Private placement of 570,000 warrants were carried out in January · Phase I trials began in April and was completed in November · At the AGM in April, Leif Darner was appointed a new Board member · The holding in the financial asset I-Tech increased by 312,500 shares in a rights issue in July · In August, Vicore Pharma